amlodipine and Chronic Kidney Failure studies

Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.

Research Excerpts

Excerpt	Relevance	Reference
"Chlorthalidone is a very effective antihypertensive drug, but it has not been studied prospectively in kidney transplant recipients with hypertension."	9.24	Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial. ( Hesselink, DA; Hoorn, EJ; Moes, AD; van den Meiracker, AH; Zietse, R, 2017)
"Amlodipine, not aliskiren, effectively reduces BP in CKD patients with refractory hypertension undergoing HD."	9.19	Effect of aliskiren in chronic kidney disease patients with refractory hypertension undergoing hemodialysis: a randomized controlled multicenter study. ( Hara, Y; Hosoya, T; Kuriyama, S; Sugano, N; Yokoo, T; Yokoyama, K, 2014)
"We examined the effects of 2 calcium channel blockers, benidipine (T-, L-, and N-type) and amlodipine (L- and N-type), on renal, inflammatory, oxidative, and atherosclerosis markers in hypertensive patients with mild chronic kidney disease (CKD)."	9.14	Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosis markers in early-stage chronic kidney disease. ( Fujiwara, N; Kawagoe, Y; Koide, H; Nakamura, T; Sato, E; Sugaya, T; Ueda, Y; Yamada, S; Yamagishi, S, 2010)
" Thirty chronically hemodialyzed uremic patients with hypertension were randomly assigned to receive the AT1-R antagonist losartan (n = 10), the angiotensin-converting enzyme (ACD) inhibitor enalapril (n = 10), or calcium antagonist amlodipine (n = 10)."	9.10	Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. ( Iwasaka, T; Masaki, H; Matsubara, H; Nishikawa, M; Nishiue, T; Shibasaki, Y, 2002)
"Ramipril, compared with amlodipine, retards renal disease progression in patients with hypertensive renal disease and proteinuria and may offer benefit to patients without proteinuria."	9.09	Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. ( Agodoa, LY; Appel, L; Bakris, GL; Beck, G; Bourgoignie, J; Briggs, JP; Charleston, J; Cheek, D; Cleveland, W; Douglas, JG; Douglas, M; Dowie, D; Faulkner, M; Gabriel, A; Gassman, J; Greene, T; Hall, Y; Hebert, L; Hiremath, L; Jamerson, K; Johnson, CJ; Kopple, J; Kusek, J; Lash, J; Lea, J; Lewis, JB; Lipkowitz, M; Massry, S; Middleton, J; Miller, ER; Norris, K; O'Connor, D; Ojo, A; Phillips, RA; Pogue, V; Rahman, M; Randall, OS; Rostand, S; Schulman, G; Smith, W; Thornley-Brown, D; Tisher, CC; Toto, RD; Wright, JT; Xu, S, 2001)
"Amlodipine is a dihydropyridine calcium channel blocker that is used in the management of both hypertension and angina."	7.78	Amlodipine-induced gingival hyperplasia in chronic renal failure: a case report. ( Aldemir, NM; Begenik, H; Emre, H; Erdur, FM; Soyoral, Y, 2012)
"Insulin resistance was calculated using fasting glucose and insulin, expressed as HOMA-IR."	6.74	Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. ( Guo, LL; Jin, HM; Pan, Y, 2009)
"Thirty-nine ESRD patients with hypertension were randomly assigned to receive losartan (n=13), enalapril (n=13), or amlodipine (n=13)."	6.71	Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. ( Iwasaka, T; Masaki, H; Matsubara, H; Matsumoto, N; Mori, Y; Nishikawa, M; Nishiue, T; Shibasaki, Y; Tamura, K, 2005)
"Insulin resistance (IR) in chronic renal failure (CRF) is well-known."	6.70	Doxazosin, but not amlodipine decreases insulin resistance in patients with chronic renal failure: a prospective, randomized-controlled study. ( Akkaya, V; Celik, AV; Gürol, AO; Hursit, M; Karsidag, K; Kayacan, SM; Yazici, H; Yildiz, A, 2002)
"Dialysate effluent leukocytosis is consistent with a greater degree of infection or inflammation in patients receiving peritoneal dialysis."	5.35	Association between peritoneal dialysate effluent leukocytosis and amlodipine besylate. ( Lee, F; Yu, MC, 2009)
"Chlorthalidone is a very effective antihypertensive drug, but it has not been studied prospectively in kidney transplant recipients with hypertension."	5.24	Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial. ( Hesselink, DA; Hoorn, EJ; Moes, AD; van den Meiracker, AH; Zietse, R, 2017)
"Amlodipine, not aliskiren, effectively reduces BP in CKD patients with refractory hypertension undergoing HD."	5.19	Effect of aliskiren in chronic kidney disease patients with refractory hypertension undergoing hemodialysis: a randomized controlled multicenter study. ( Hara, Y; Hosoya, T; Kuriyama, S; Sugano, N; Yokoo, T; Yokoyama, K, 2014)
"Ramipril attenuates renal Fibroblast growth factor-23 (FGF-23) expression, ameliorates proteinuria and normalizes serum phosphate in the diabetic Zucker rat with progressive renal disease suggesting that the renoprotective effect by this drug may be in part due to a FGF-23-lowering effect of angiotensin-converting enzyme (ACE) inhibition."	5.19	Ramipril lowers plasma FGF-23 in patients with diabetic nephropathy. ( Cetinkaya, H; Eyileten, T; Gok, M; Karaman, M; Kurt, YG; Mallamaci, F; Oguz, Y; Saglam, M; Sonmez, A; Unal, HU; Vural, A; Yilmaz, MI; Zoccali, C, 2014)
"The ACCOMPLISH trial (Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension) was a 3-year multicenter, event-driven trial involving patients with high cardiovascular risk who were randomized in a double-blinded manner to benazepril plus either hydrochlorothiazide or amlodipine and titrated in parallel to reach recommended blood pressure goals."	5.16	Renal outcomes in hypertensive Black patients at high cardiovascular risk. ( Bakris, GL; Dahlof, B; Devereux, RB; Hester, RA; Hua, TA; Jamerson, KA; Kelly, RY; Kjeldsen, SE; Pitt, B; Velazquez, E; Weber, MA; Weir, MR; Wright, JT, 2012)
"There was evidence of pharmacogenetic effects of FGB-455 on stroke, ESRD, and mortality, suggesting that relative to those homozygous for the common allele, variant allele carriers of the FGB gene at position -455 have a better outcome if randomized to lisinopril than chlorthalidone (for mortality and ESRD) or amlodipine (for mortality and stroke)."	5.14	Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study. ( Arnett, DK; Boerwinkle, E; Davis, BR; Eckfeldt, JH; Ford, CE; Leiendecker-Foster, C; Lynch, AI, 2009)
"We examined the effects of 2 calcium channel blockers, benidipine (T-, L-, and N-type) and amlodipine (L- and N-type), on renal, inflammatory, oxidative, and atherosclerosis markers in hypertensive patients with mild chronic kidney disease (CKD)."	5.14	Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosis markers in early-stage chronic kidney disease. ( Fujiwara, N; Kawagoe, Y; Koide, H; Nakamura, T; Sato, E; Sugaya, T; Ueda, Y; Yamada, S; Yamagishi, S, 2010)
"The Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial showed that initial antihypertensive therapy with benazepril plus amlodipine was superior to benazepril plus hydrochlorothiazide in reducing cardiovascular morbidity and mortality."	5.14	Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. ( Bakris, GL; Chiang, YT; Dahlöf, B; Jamerson, K; Kelly, RY; Pitt, B; Sarafidis, PA; Shi, V; Staikos-Byrne, L; Velazquez, EJ; Weber, MA; Weir, MR, 2010)
"BP control with ramipril or amlodipine could not provide adequate protection for development or progression of atherosclerosis and eccentric type of LVH in nondiabetic HD patients."	5.14	Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients. ( Akinci, D; Altun, B; Kahraman, S; Ozer, N; Turgan, C; Yilmaz, R, 2010)
"To compare rates of coronary heart disease (CHD) and end-stage renal disease (ESRD) events; to determine whether glomerular filtration rate (GFR) independently predicts risk for CHD; and to report the efficacy of first-step treatment with a calcium-channel blocker (amlodipine) or an angiotensin-converting enzyme inhibitor (lisinopril), each compared with a diuretic (chlorthalidone), in modifying cardiovascular disease (CVD) outcomes in high-risk patients with hypertension stratified by GFR."	5.12	Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. ( Barzilay, J; Batuman, V; Davis, BR; Eckfeldt, JH; Farber, MA; Franklin, S; Henriquez, M; Kopyt, N; Louis, GT; Nwachuku, C; Pressel, S; Rahman, M; Saklayen, M; Stanford, C; Walworth, C; Ward, H; Whelton, PK; Wiegmann, T; Wright, JT, 2006)
" Using treatment-specific probabilities derived from the Irbesartan in Diabetic Nephropathy Trial (IDNT), the cost effectiveness of treating patients with hypertension, type II diabetes and nephropathy with irbesartan, amlodipine or control was calculated using a Markov model."	5.11	An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting. ( Annemans, L; Bilous, RW; Lamotte, M; Palmer, AJ; Rodby, RA; Roze, S, 2004)
" A new clinical trial, GUARD (Gauging Albuminuria Reduction With Lotrel in Diabetic Patients With Hypertension), is designed to compare the change in urinary albumin to creatinine ratio after 1 year of initial treatment with either amlodipine besylate/benazepril HCl or benazepril HCl/hydrochlorothiazide."	5.11	Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension. ( Bakris, GL; McCullough, PA; Toto, RD, 2005)
" Hypertensive participants 55 years or older with at least 1 other coronary heart disease risk factor were randomized to receive chlorthalidone, amlodipine, or lisinopril for a mean of 4."	5.11	Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ( Barzilay, J; Batuman, V; Davis, BR; Eckfeldt, JH; Farber, M; Henriquez, M; Kopyt, N; Louis, GT; Nwachuku, C; Pressel, S; Rahman, M; Saklayen, M; Stanford, C; Walworth, C; Ward, H; Whelton, PK; Wiegmann, T; Wright, JT, 2005)
"The African American Study of Kidney Disease and Hypertension examined the effect on renal function decline of 2 blood pressure (BP) goals (low mean arterial pressure [MAP] < or =92 versus usual MAP 102 to 107 mm Hg) and 3 antihypertensives (ramipril versus amlodipine versus metoprolol)."	5.11	Blood pressure control, drug therapy, and kidney disease. ( Agodoa, LY; Cheek, D; Contreras, G; Dowie, D; Greene, T; Junco, G; Lash, J; Lipkowitz, M; Miller, ER; Ojo, A; Sika, M; Toto, RD; Wilkening, B, 2005)
"High-dose losartan increases rHuEPO requirement and should be reserved for dialysis patients with hypertension uncontrollable with other antihypertensive medications."	5.10	The effect of high dose losartan on erythropoietin resistance in patients undergoing haemodialysis. ( Bilen, H; Cetinkaya, R; Keles, S; Odabas, AR; Selcuk, Y, 2003)
" Thirty chronically hemodialyzed uremic patients with hypertension were randomly assigned to receive the AT1-R antagonist losartan (n = 10), the angiotensin-converting enzyme (ACD) inhibitor enalapril (n = 10), or calcium antagonist amlodipine (n = 10)."	5.10	Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. ( Iwasaka, T; Masaki, H; Matsubara, H; Nishikawa, M; Nishiue, T; Shibasaki, Y, 2002)
"We studied muscle sympathetic-nerve activity in 14 patients with hypertension, chronic renal failure, and increased plasma renin activity before, during, and after administration of the ACE inhibitor enalapril."	5.09	Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. ( Blankestijn, PJ; Boomsma, F; Dijkhorst-Oei, LT; Klein, IH; Koomans, HA; Ligtenberg, G; Oey, PL; van Huffelen, AC; Wieneke, GH, 1999)
"Ramipril, compared with amlodipine, retards renal disease progression in patients with hypertensive renal disease and proteinuria and may offer benefit to patients without proteinuria."	5.09	Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. ( Agodoa, LY; Appel, L; Bakris, GL; Beck, G; Bourgoignie, J; Briggs, JP; Charleston, J; Cheek, D; Cleveland, W; Douglas, JG; Douglas, M; Dowie, D; Faulkner, M; Gabriel, A; Gassman, J; Greene, T; Hall, Y; Hebert, L; Hiremath, L; Jamerson, K; Johnson, CJ; Kopple, J; Kusek, J; Lash, J; Lea, J; Lewis, JB; Lipkowitz, M; Massry, S; Middleton, J; Miller, ER; Norris, K; O'Connor, D; Ojo, A; Phillips, RA; Pogue, V; Rahman, M; Randall, OS; Rostand, S; Schulman, G; Smith, W; Thornley-Brown, D; Tisher, CC; Toto, RD; Wright, JT; Xu, S, 2001)
"Treatment of hypertension with CCBs should take into consideration the special effects of each single agent at different levels; lercanidipine for example may play a useful role in the management not only of hypertension but also in renal protection of hypertensive patients."	4.89	Renal protection with calcium antagonists: the role of lercanidipine. ( Burnier, M, 2013)
"Currently, AIIAs such as losartan represent the only evidence-based treatment strategy for patients with type 2 DM and proteinuria."	4.82	Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence. ( Ruilope, LM; Segura, J, 2003)
"SEVERAL MECHANISMS: The progression in renal failure first implies hemodynamic mechanisms and among which angiotensin II has a central role, but also an increase in proteinuria and the induction of many inflammatory and mitogenic mediators that enhance fibrosis (TGF-beta), an effect stimulating the thrombotic mechanism."	4.81	[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure]. ( Bernadet-Monrozies, P; Durand, D; Kamar, N; Rostaing, L, 2002)
"Amlodipine is a dihydropyridine calcium channel blocker that is used in the management of both hypertension and angina."	3.78	Amlodipine-induced gingival hyperplasia in chronic renal failure: a case report. ( Aldemir, NM; Begenik, H; Emre, H; Erdur, FM; Soyoral, Y, 2012)
"Diabetic nephropathy is the most common cause of end-stage renal disease (ESRD) in the United States, and accounts for 35% of all the patients with ESRD entering a dialysis program; 63% of patients with diabetic nephropathy have type II diabetes mellitus."	3.78	Renoprotection and renin-angiotensin system blockade in diabetes mellitus. ( Ruilope, LM, 1997)
"The irbesartan in Diabetic Nephropathy Trial (IDNT) demonstrated that treatment of patients with type 2 diabetes, hypertension and nephropathy with irbesartan resulted in a 20% relative reduction of the composite endpoint of doubling serum creatinine, end-stage renal disease or death as compared with amlodipine and placebo (antihypertensive standard therapy)."	3.73	[Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland]. ( Burnier, M; Frei, A; Hess, B; Palmer, AJ, 2006)
"Treating patients with hypertension, type 2 diabetes and nephropathy using irbesartan lowers the cumulative incidence of ESRD and is cost-saving compared to amlodipine or control."	3.72	[Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension]. ( Annemans, L; Lamotte, M; Palmer, AJ; Ritz, E; Rodby, RA; Roze, S, 2004)
"Insulin resistance was calculated using fasting glucose and insulin, expressed as HOMA-IR."	2.74	Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. ( Guo, LL; Jin, HM; Pan, Y, 2009)
"Patients with end-stage renal disease (ESRD) receiving hemodialysis (HD) treatment have a markedly shortened life expectancy in large part owing to cardiovascular disease (CVD), not explained by established risk factors."	2.72	Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. ( Aslam, S; Leone, A; Santha, T; Wilcox, C, 2006)
"The primary outcomes of the Irbesartan Diabetic Nephropathy Trial were doubling of serum creatinine levels, end-stage renal disease, and death from any cause."	2.71	Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. ( Berl, T; Drury, PL; Esmatjes, E; Goldhaber, SZ; Hricik, D; Hunsicker, LG; Lewis, EJ; Lewis, JB; Locatelli, F; Parikh, CR; Pfeffer, MA; Porush, JG; Raz, I; Rouleau, JL; Vanhille, P; Wiegmann, TB; Wolfe, BM, 2003)
"Losartan was administered once daily at doses of 25 to 100 mg/day, and amlodipine was given once daily at 2."	2.71	Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for ( Hayashi, M; Ideura, T; Iino, Y; Kawaguchi, Y; Kawamura, T; Kitajima, T; Koyama, A; Kuwahara, M; Shiigai, T; Sugisaki, T; Suzuki, H; Tomino, Y; Uchida, S; Umemura, S; Yamada, K; Yamazaki, T, 2003)
"Thirty-nine ESRD patients with hypertension were randomly assigned to receive losartan (n=13), enalapril (n=13), or amlodipine (n=13)."	2.71	Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. ( Iwasaka, T; Masaki, H; Matsubara, H; Matsumoto, N; Mori, Y; Nishikawa, M; Nishiue, T; Shibasaki, Y; Tamura, K, 2005)
"Hypertension is a leading cause of end-stage renal disease (ESRD) in the United States, with no known treatment to prevent progressive declines leading to ESRD."	2.70	Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. ( Agodoa, LY; Appel, LJ; Bakris, G; Charleston, J; Cheek, D; Douglas-Baltimore, JG; Gassman, J; Glassock, R; Greene, T; Hebert, L; Jamerson, K; Lewis, J; Middleton, JP; Phillips, RA; Rostand, SG; Toto, RD; Wright, JT, 2002)
"Insulin resistance (IR) in chronic renal failure (CRF) is well-known."	2.70	Doxazosin, but not amlodipine decreases insulin resistance in patients with chronic renal failure: a prospective, randomized-controlled study. ( Akkaya, V; Celik, AV; Gürol, AO; Hursit, M; Karsidag, K; Kayacan, SM; Yazici, H; Yildiz, A, 2002)
"Hypertension is the second leading attributable cause of end-stage renal disease in the United States today."	2.43	Lessons from the African-American Study of Kidney Disease and Hypertension: an update. ( Toto, RD, 2006)
"Patients with type 2 diabetes and diabetic nephropathy have a dramatically increased cardiovascular risk."	2.42	Treatment of diabetic nephropathy with angiotensin II receptor antagonist. ( Lewis, EJ; Lewis, JB, 2003)
"The association was similar when ESRD and a 50% decline in eGFR were analyzed separately, for other measures of visit-to-visit variability of systolic BP, and for visit-to-visit variability of diastolic BP."	1.43	Visit-to-Visit Variability of BP and CKD Outcomes: Results from the ALLHAT. ( Davis, BR; Lynch, AI; Muntner, P; Oparil, S; Rahman, M; Simpson, LM; Tanner, RM; Whelton, PK; Whittle, J, 2016)
"The aims of this study are to find the prevalence of potential drug-drug interactions (DDIs) in patients with Hemodialysis and identify factors associated with these interactions if present."	1.43	Evaluation of potential drug- drug interactions among Palestinian hemodialysis patients. ( Abu-Ghazaleh, D; Al-Ramahi, R; Bsharat, A; Raddad, AR; Rashed, AO; Shehab, O; Yasin, E, 2016)
"In patients with established Type 2 diabetic nephropathy and CKD Stages 1-5, irbesartan safely and significantly slowed the rate of ΔeGFR decline (-2."	1.38	Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial. ( Bain, SC; Bilous, RW; Evans, M; Hogan, S, 2012)
"Dialysate effluent leukocytosis is consistent with a greater degree of infection or inflammation in patients receiving peritoneal dialysis."	1.35	Association between peritoneal dialysate effluent leukocytosis and amlodipine besylate. ( Lee, F; Yu, MC, 2009)
"Both in CHF (congestive heart failure) and CRI (chronic renal insufficiency), blood pressure reduction is beneficial for preservation of cardiac and renal function."	1.31	Intensive blood pressure reduction is beneficial in patients with impaired cardiac function coexisting with chronic renal insufficiency. ( Ikeda, N; Kanno, Y; Moriwaki, K; Nakamoto, H; Okada, H; Sugahara, S; Suzuki, H, 2002)
"Proteinuria was reduced with both drugs."	1.31	Influence of the timing of initiating antihypertensive therapy in hypertensive rats with renal failure. ( Kanno, Y; Okada, H; Saruta, T; Suzuki, H; Takenaka, T, 2000)
"It is concluded that chronic renal failure is associated with deranged calcium homeostasis of PMNLs which causes abnormalities in the function of Fcgamma RIII receptors and consequently results in impaired phagocytosis."	1.30	Effect of amlodipine therapy on the monoclonal antibody 3G8-induced calcium signal in polymorphonuclear leukocytes of hemodialysis patients. ( Ahmed, A; Krol, E; Massry, SG; Smogorzewski, M, 1999)

Research

Studies (72)

Authors

Clinical Trials (12)

Trial Overview

Trial Outcomes

Time-to-event Analysis of Percentage of Patients With a Cardiovascular (CV) Mortality Event, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	5 (6.94)	18.2507
2000's	44 (61.11)	29.6817
2010's	22 (30.56)	24.3611
2020's	1 (1.39)	2.80

Authors	Studies
Youssef, AM	1
Elghoneimy, HA	1
Helmy, MW	1
Abdelazeem, AM	1
El-Khodary, NM	1
Zahed, NS	1
Hassanian-Moghaddam, H	1
Zamani, N	1
Jeon, SY	1
Lee, NR	1
Yim, CY	1
Aldemir, NM	1
Begenik, H	1
Emre, H	1
Erdur, FM	1
Soyoral, Y	1
Burnier, M	2
Kuriyama, S	1
Yokoyama, K	1
Hara, Y	1
Sugano, N	1
Yokoo, T	1
Hosoya, T	1
Uchida, S	3
Takahashi, M	1
Sugawara, M	1
Saito, T	1
Nakai, K	1
Fujita, M	1
Mochizuki, K	1
Shin, I	1
Morita, T	1
Hikita, T	1
Itakura, H	1
Takahashi, Y	1
Mizuno, S	1
Ohno, Y	1
Ito, K	1
Ito, T	1
Soma, M	1
Yilmaz, MI	1
Sonmez, A	1
Saglam, M	1
Kurt, YG	1
Unal, HU	1
Karaman, M	1
Gok, M	1
Cetinkaya, H	1
Eyileten, T	1
Oguz, Y	1
Vural, A	1
Mallamaci, F	1
Zoccali, C	2
Statsenko, ME	1
Derevyanchenko, MV	1
Whittle, J	1
Lynch, AI	2
Tanner, RM	1
Simpson, LM	1
Davis, BR	5
Rahman, M	5
Whelton, PK	4
Oparil, S	2
Muntner, P	1
Robertson, LM	1
Frith, JA	1
Tcheurekdjian, H	1
Hostoffer, RW	1
Al-Ramahi, R	1
Raddad, AR	1
Rashed, AO	1
Bsharat, A	1
Abu-Ghazaleh, D	1
Yasin, E	1
Shehab, O	1
Moes, AD	1
Hesselink, DA	1
van den Meiracker, AH	1
Zietse, R	1
Hoorn, EJ	1
Guo, LL	1
Pan, Y	1
Jin, HM	1
Lee, F	1
Yu, MC	1
Abe, M	1
Okada, K	1
Maruyama, T	1
Maruyama, N	1
Matsumoto, K	1
Wallace, EL	1
Lingle, K	1
Pierce, D	1
Satko, S	1
Boerwinkle, E	1
Ford, CE	2
Eckfeldt, JH	3
Leiendecker-Foster, C	1
Arnett, DK	1
Nakamura, T	2
Sato, E	1
Fujiwara, N	1
Kawagoe, Y	2
Ueda, Y	2
Sugaya, T	2
Yamagishi, S	1
Yamada, S	1
Koide, H	2
Heerspink, HL	1
de Zeeuw, D	1
Bakris, GL	4
Sarafidis, PA	1
Weir, MR	2
Dahlöf, B	2
Pitt, B	2
Jamerson, K	3
Velazquez, EJ	1
Staikos-Byrne, L	1
Kelly, RY	2
Shi, V	1
Chiang, YT	1
Weber, MA	2
Schorn, R	1
Gaspert, A	1
Cohen, CD	1
Nakano, N	1
Ishimitsu, T	1
Takahashi, T	1
Inada, H	1
Okamura, A	1
Ohba, S	1
Matsuoka, H	1
Yilmaz, R	1
Altun, B	2
Kahraman, S	1
Ozer, N	1
Akinci, D	1
Turgan, C	1
Takano, H	1
Hasegawa, H	1
Narumi, H	1
Shindo, S	1
Mizuma, H	1
Kuwabara, Y	1
Kobayashi, Y	1
Komuro, I	1
Evans, M	1
Bain, SC	1
Hogan, S	1
Bilous, RW	2
Devereux, RB	1
Kjeldsen, SE	1
Wright, JT	6
Hua, TA	1
Hester, RA	1
Velazquez, E	1
Jamerson, KA	1
Cutler, JA	1
Piller, LB	1
Barzilay, JI	1
Brown, CD	1
Colon, PJ	1
Fine, LJ	1
Grimm, RH	1
Gupta, AK	1
Baimbridge, C	1
Haywood, LJ	1
Henriquez, MA	1
Ilamaythi, E	1
Preston, R	1
Shibasaki, Y	3
Nishiue, T	3
Masaki, H	3
Matsubara, H	3
Iwasaka, T	3
Suzuki, H	6
Bakris, G	1
Greene, T	3
Agodoa, LY	3
Appel, LJ	1
Charleston, J	2
Cheek, D	3
Douglas-Baltimore, JG	1
Gassman, J	2
Glassock, R	1
Hebert, L	2
Lewis, J	1
Phillips, RA	2
Toto, RD	5
Middleton, JP	1
Rostand, SG	1
Bernadet-Monrozies, P	1
Rostaing, L	1
Kamar, N	1
Durand, D	1
Yildiz, A	1
Hursit, M	1
Celik, AV	1
Kayacan, SM	1
Yazici, H	1
Akkaya, V	1
Gürol, AO	1
Karsidag, K	1
Fukuda, M	1
Usami, T	1
Yoshida, A	1
Kimura, G	1
Berl, T	2
Hunsicker, LG	2
Lewis, JB	4
Pfeffer, MA	1
Porush, JG	1
Rouleau, JL	1
Drury, PL	1
Esmatjes, E	1
Hricik, D	1
Parikh, CR	1
Raz, I	2
Vanhille, P	1
Wiegmann, TB	1
Wolfe, BM	1
Locatelli, F	1
Goldhaber, SZ	1
Lewis, EJ	3
Odabas, AR	1
Cetinkaya, R	1
Selcuk, Y	1
Keles, S	1
Bilen, H	1
Morrone, LF	1
Ramunni, A	1
Fassianos, E	1
Saracino, A	1
Coratelli, P	1
Passavanti, G	1
Iino, Y	2
Hayashi, M	2
Kawamura, T	2
Shiigai, T	2
Tomino, Y	2
Yamada, K	2
Kitajima, T	2
Ideura, T	2
Koyama, A	2
Sugisaki, T	2
Umemura, S	2
Kawaguchi, Y	1
Kuwahara, M	2
Yamazaki, T	2
Palmer, AJ	3
Annemans, L	2
Roze, S	2
Lamotte, M	2
Rodby, RA	2
Ritz, E	2
Ruilope, LM	2
Segura, J	1
Kawaguchii, Y	1
McCullough, PA	1
Pressel, S	2
Nwachuku, C	2
Barzilay, J	2
Batuman, V	2
Farber, M	1
Henriquez, M	2
Kopyt, N	2
Louis, GT	2
Saklayen, M	2
Stanford, C	2
Walworth, C	2
Ward, H	2
Wiegmann, T	2
Contreras, G	1
Junco, G	1
Dowie, D	2
Lash, J	2
Lipkowitz, M	2
Miller, ER	2
Ojo, A	2
Sika, M	1
Wilkening, B	1
MacGregor, MS	1
Deighan, CJ	1
Rodger, RS	1
Boulton-Jones, JM	1
Formica, RN	1
Friedman, AL	1
Lorber, MI	1
Smith, JD	1
Eisen, T	1
Bia, MJ	1
Farber, MA	1
Franklin, S	1
Tamura, K	1
Matsumoto, N	1
Mori, Y	1
Nishikawa, M	2
Frei, A	1
Hess, B	1
Aslam, S	1
Santha, T	1
Leone, A	1
Wilcox, C	1
Suzuki, T	1
Inoue, T	1
Node, K	1
Yee, J	1
August, P	1
Lenz, T	1
Laragh, JH	1
Ligtenberg, G	1
Blankestijn, PJ	1
Oey, PL	1
Klein, IH	1
Dijkhorst-Oei, LT	1
Boomsma, F	1
Wieneke, GH	1
van Huffelen, AC	1
Koomans, HA	1
Ahmed, A	1
Krol, E	1
Smogorzewski, M	1
Massry, SG	1
Usalan, C	1
Erdem, Y	1
Arici, M	1
Kanno, Y	2
Okada, H	2
Takenaka, T	1
Saruta, T	1
Appel, L	1
Beck, G	1
Bourgoignie, J	1
Briggs, JP	1
Cleveland, W	1
Douglas, JG	1
Douglas, M	1
Faulkner, M	1
Gabriel, A	1
Hall, Y	1
Hiremath, L	1
Johnson, CJ	1
Kopple, J	1
Kusek, J	1
Lea, J	1
Massry, S	1
Middleton, J	1
Norris, K	1
O'Connor, D	1
Pogue, V	1
Randall, OS	1
Rostand, S	1
Schulman, G	1
Smith, W	1
Thornley-Brown, D	1
Tisher, CC	1
Xu, S	1
Vidt, DG	1
Clarke, WR	1
Pohl, MA	1
Atkins, RC	1
Rohde, R	1
McConaghy, JR	1
Ikeda, N	1
Moriwaki, K	1
Sugahara, S	1
Nakamoto, H	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Effect of Amlodipine Versus Bisoprolol on Hypertensive Patients With End-stage Renal Disease on Maintenance Hemodialysis.[NCT04085562]	Phase 4	46 participants (Actual)	Interventional	2019-09-01	Completed
[NCT01738945]	Phase 4	32 participants (Actual)	Interventional	2008-02-29	Completed
Thiazide Diuretics for Hypertension in Kidney Transplant Recipients Using Tacrolimus[NCT02644395]	Phase 3	49 participants (Actual)	Interventional	2013-01-18	Completed
Pilot Study to Assess Blockade of Calcium Channels and Sodium Chloride Cotransporters for Physiologic Abnormalities in Liver Transplant Associated Hypertension[NCT05275907]	Phase 4	0 participants (Actual)	Interventional	2022-07-12	Withdrawn (stopped due to Screened participants did not meet inclusion criteria prior to study completion date)
A Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension[NCT00170950]	Phase 3	11,506 participants (Actual)	Interventional	2003-10-31	Terminated (stopped due to The study was terminated early because of significant efficacy results for the primary endpoint in favor of benazepril/amlodipine treatment.)
Medication Adherence Given Individual SystemCHANGE(TM) in Advancing Nephropathy (MAGICIAN) Pilot Study[NCT04616612]		150 participants (Anticipated)	Interventional	2021-12-15	Recruiting
[NCT00000542]	Phase 3	0 participants	Interventional	1993-08-31	Completed
African American Study of Kidney Disease and Hypertension[NCT04364139]	Phase 3	1,094 participants (Actual)	Interventional	1995-02-01	Completed
Effect of Renin-angiotensin-system (RAS) Blocker Drugs on Chronic Kidney Disease (CKD) Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01)[NCT03195023]	Phase 4	106 participants (Anticipated)	Interventional	2015-06-30	Recruiting
A Randomised Open Label, Blinded End Point Trial to Compare the Effects of Spironolactone With Chlortalidone on LV Mass in Stage 3 Chronic Kidney Disease (SPIRO-CKD)[NCT02502981]	Phase 4	154 participants (Actual)	Interventional	2014-06-30	Active, not recruiting
Open, Randomized, Unicenter Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease[NCT04626323]	Phase 2	60 participants (Anticipated)	Interventional	2021-05-25	Recruiting
Determinants of Diabetic Nephropathy in American Indians[NCT01878045]		141 participants (Actual)	Observational	2013-11-07	Suspended (stopped due to This study is on a temporary Administrative Hold pending further discussion for NIDDK and Tribal Leadership.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

CV mortality was defined as death due to sudden cardiac death, fatal MI, fatal stroke, coronary intervention, congestive heart failure (CHF), or other CV causes. (NCT00170950)
Timeframe: For each patient, baseline to time of first CV mortality event, MI (non-fatal), or stroke (non-fatal) (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])

Time-to-event Analysis of Percentage of Patients With a Composite Cardiovascular (CV) Morbidity Event

Intervention	Percentage of Patients with an Event (Number)
Benazepril/Amlodipine	5.0
Benazepril/Hydrochlorothiazide	6.3

Cardiovascular morbidity was defined as including any of the following events: non-fatal MI, non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure (PCI or CABG). (NCT00170950)
Timeframe: For each patient, baseline to time of first CV morbidity event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])]

Time-to-event Analysis of Percentage of Patients With a Composite Cardiovascular (CV) Morbidity or Mortality Event

Intervention	Percentage of Patients with an Event (Number)
Benazepril/Amlodipine	8.6
Benazepril/Hydrochlorothiazide	10.3

CV morbidity was defined as non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure. CV mortality was defined as death due to MI, stroke, coronary intervention, congestive heart failure (CHF), sudden cardiac death, or other CV causes. (NCT00170950)
Timeframe: For each patient, baseline to time of first CV morbidity or mortality event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])

Article	Year
Renal protection with calcium antagonists: the role of lercanidipine. Current medical research and opinion, 2013, Volume: 29, Issue:12 Topics: Amlodipine; Calcium Channel Blockers; Dihydropyridines; Female; Humans; Hypertension; Kidney Failure	2013
[Large scale clinical trials in prevention of end-stage renal disease due to type 2 diabetes with angiotensin receptor antagonists]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60, Issue:10 Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Clinical Trials as Topic;	2002
[Evidence for the benefits of ACE inhibitors and AII antagonists in slowing progressive renal failure in diabetes]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 10 Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Com	2002
[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure]. Presse medicale (Paris, France : 1983), 2002, Nov-09, Volume: 31, Issue:36 Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito	2002
Treatment of diabetic nephropathy with angiotensin II receptor antagonist. Clinical and experimental nephrology, 2003, Volume: 7, Issue:1 Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Creatinin	2003
Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence. Clinical therapeutics, 2003, Volume: 25, Issue:12 Topics: Albuminuria; Amlodipine; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Clinical Trial	2003
Lessons from the African-American Study of Kidney Disease and Hypertension: an update. Current hypertension reports, 2006, Volume: 8, Issue:5 Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive	2006
Asymmetric dimethylarginine in end-stage renal disease patients: a biomarker modifiable by calcium blockade and angiotensin II antagonism? Kidney international, 2006, Volume: 70, Issue:12 Topics: Amlodipine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Arginine; Biomarkers; Calcium;	2006
Renoprotection and renin-angiotensin system blockade in diabetes mellitus. American journal of hypertension, 1997, Volume: 10, Issue:12 Pt 2 Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetic	1997

Article	Year
Effect of amlodipine versus bisoprolol in hypertensive patients on maintenance hemodialysis: A randomized controlled trial. Medicine, 2021, Dec-23, Volume: 100, Issue:51 Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Pressure; Female; Humans; Hypert	2021
Effect of aliskiren in chronic kidney disease patients with refractory hypertension undergoing hemodialysis: a randomized controlled multicenter study. Clinical and experimental nephrology, 2014, Volume: 18, Issue:5 Topics: Aged; Amides; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Female; Fumarates; Huma	2014
Effects of the N/L-type calcium channel blocker cilnidipine on nephropathy and uric acid metabolism in hypertensive patients with chronic kidney disease (J-CIRCLE study). Journal of clinical hypertension (Greenwich, Conn.), 2014, Volume: 16, Issue:10 Topics: Aged; Aged, 80 and over; Albuminuria; Amlodipine; Blood Pressure; Calcium Channel Blockers; Creatini	2014
Ramipril lowers plasma FGF-23 in patients with diabetic nephropathy. American journal of nephrology, 2014, Volume: 40, Issue:3 Topics: Adult; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Diabetes Mellitus, Type	2014
[Cardio-Nephroprotection--the Most Important Goal of Antihypertensive Therapy in Patients With Type 2 Diabetes]. Kardiologiia, 2015, Volume: 55, Issue:8 Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel B	2015
Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017, Volume: 69, Issue:6 Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Chlorthalidone; Cr	2017
Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017, Volume: 69, Issue:6 Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Chlorthalidone; Cr	2017
Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017, Volume: 69, Issue:6 Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Chlorthalidone; Cr	2017
Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017, Volume: 69, Issue:6 Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Chlorthalidone; Cr	2017
Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2009, Volume: 24, Issue:6 Topics: Adiponectin; Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diabe	2009
Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3-5 chronic kidney disease. Hypertension research : official journal of the Japanese Society of Hypertension, 2009, Volume: 32, Issue:4 Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Dihydropyridine	2009
Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study. Pharmacogenetics and genomics, 2009, Volume: 19, Issue:6 Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel	2009
Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosis markers in early-stage chronic kidney disease. The American journal of the medical sciences, 2010, Volume: 339, Issue:2 Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Amlodipine; Atherosclerosis; Biomarkers; Calcium Channel Blocker	2010
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet (London, England), 2010, Apr-03, Volume: 375, Issue:9721 Topics: Aged; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Be	2010
Effects of efonidipine, an L- and T-type calcium channel blocker, on the renin-angiotensin-aldosterone system in chronic hemodialysis patients. International heart journal, 2010, Volume: 51, Issue:3 Topics: Aged; Aldosterone; Amlodipine; Blood Pressure; Calcium Channel Blockers; Calcium Channels, L-Type; C	2010
Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients. Renal failure, 2010, Volume: 32, Issue:8 Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atherosclerosis; Carotid Arteries; Female; Heart V	2010
Effects of valsartan and amlodipine on home blood pressure and cardiovascular events in Japanese hypertensive patients: a subanalysis of the VART. Journal of human hypertension, 2012, Volume: 26, Issue:11 Topics: Aged; Albuminuria; Amlodipine; Angina Pectoris; Antihypertensive Agents; Asian People; Blood Pressur	2012
Renal outcomes in hypertensive Black patients at high cardiovascular risk. Kidney international, 2012, Volume: 81, Issue:6 Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; B	2012
Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR. Clinical journal of the American Society of Nephrology : CJASN, 2012, Volume: 7, Issue:6 Topics: Amlodipine; Antihypertensive Agents; Canada; Chlorthalidone; Chronic Disease; Coronary Disease; Doub	2012
[Angiotensin II type 1 antagonist suppress left ventricular hypertrophy and myocardial fibrosis in patient with end stage renal disease (ESRD)]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60, Issue:10 Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Chan	2002
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA, 2002, Nov-20, Volume: 288, Issue:19 Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti	2002
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA, 2002, Nov-20, Volume: 288, Issue:19 Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti	2002
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA, 2002, Nov-20, Volume: 288, Issue:19 Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti	2002
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA, 2002, Nov-20, Volume: 288, Issue:19 Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti	2002
Doxazosin, but not amlodipine decreases insulin resistance in patients with chronic renal failure: a prospective, randomized-controlled study. Clinical nephrology, 2002, Volume: 58, Issue:6 Topics: Adult; Amlodipine; Antihypertensive Agents; Doxazosin; Female; Homeostasis; Humans; Insulin Resistan	2002
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Annals of internal medicine, 2003, Apr-01, Volume: 138, Issue:7 Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Comp	2003
The effect of high dose losartan on erythropoietin resistance in patients undergoing haemodialysis. Panminerva medica, 2003, Volume: 45, Issue:1 Topics: Adult; Amlodipine; Anemia; Angiotensin Receptor Antagonists; Antihypertensive Agents; Dose-Response	2003
Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Clinical and experimental nephrology, 2003, Volume: 7, Issue:3 Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure;	2003
Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension--a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study. Hypertension research : official journal of the Japanese Society of Hypertension, 2004, Volume: 27, Issue:1 Topics: Aged; Amlodipine; Antihypertensive Agents; Female; Humans; Hypertension, Renal; Japan; Kidney Failur	2004
An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting. Journal of human hypertension, 2004, Volume: 18, Issue:10 Topics: Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Cohort Studies; Cost-Benefit Analysis; Diab	2004
Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension. Journal of human hypertension, 2005, Volume: 19, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; A	2005
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Archives of internal medicine, 2005, Apr-25, Volume: 165, Issue:8 Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers	2005
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Archives of internal medicine, 2005, Apr-25, Volume: 165, Issue:8 Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers	2005
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Archives of internal medicine, 2005, Apr-25, Volume: 165, Issue:8 Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers	2005
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Archives of internal medicine, 2005, Apr-25, Volume: 165, Issue:8 Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers	2005
Blood pressure control, drug therapy, and kidney disease. Hypertension (Dallas, Tex. : 1979), 2005, Volume: 46, Issue:1 Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti	2005
A prospective open-label randomised trial of quinapril and/or amlodipine in progressive non-diabetic renal failure. Nephron. Clinical practice, 2005, Volume: 101, Issue:3 Topics: Adult; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blocker	2005
A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2006, Volume: 21, Issue:5 Topics: Adult; Aged; Amlodipine; Blood Pressure Determination; Chi-Square Distribution; Dose-Response Relati	2006
Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Annals of internal medicine, 2006, Feb-07, Volume: 144, Issue:3 Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Chronic Disease;	2006
Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. Hypertension research : official journal of the Japanese Society of Hypertension, 2005, Volume: 28, Issue:10 Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Collagen; Double-Blind Method; Echocardiography	2005
Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. Kidney international, 2006, Volume: 70, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Arginine; Blood	2006
Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. The American journal of the medical sciences, 2007, Volume: 333, Issue:6 Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Amlodipine; Antioxidants; Azetidinecarboxylic Acid; Blood Pressu	2007
Renoprotection and renin-angiotensin system blockade in diabetes mellitus. American journal of hypertension, 1997, Volume: 10, Issue:12 Pt 2 Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetic	1997
Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. The New England journal of medicine, 1999, Apr-29, Volume: 340, Issue:17 Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Baroreflex; Calcium Channel Blockers; Enalapri	1999
Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA, 2001, Jun-06, Volume: 285, Issue:21 Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti	2001
Clinical trials report. The effect of Ramipril versus Amlodipine on renal outcomes in hypertension nephrosclerosis. Current hypertension reports, 2001, Volume: 3, Issue:5 Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Creatinine; Humans; H	2001
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12 Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compoun	2001
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12 Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compoun	2001
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12 Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compoun	2001
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12 Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compoun	2001
What is the best treatment for slowing the progression to end-stage renal disease (ESRD) in African Americans with hypertensive nephropathy? The Journal of family practice, 2001, Volume: 50, Issue:9 Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Black People; Double-Blind Method; Female; Glomeru	2001
Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron, 2002, Volume: 90, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihy	2002

Article	Year
A Fatal Case of Amlodipine Toxicity Following Iatrogenic Hypercalcemia. Cardiovascular toxicology, 2018, Volume: 18, Issue:3 Topics: Adult; Amlodipine; Calcium Channel Blockers; Calcium Gluconate; Electrocardiography; Fatal Outcome;	2018
Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report. BMC nephrology, 2019, 01-03, Volume: 20, Issue:1 Topics: Aged; Amlodipine; Angiogenesis Inhibitors; Antihypertensive Agents; Antineoplastic Agents; Carcinoma	2019
Amlodipine-induced gingival hyperplasia in chronic renal failure: a case report. African health sciences, 2012, Volume: 12, Issue:4 Topics: Adult; Amlodipine; Calcium Channel Blockers; Gingival Hyperplasia; Humans; Hypertension; Kidney Fail	2012
Visit-to-Visit Variability of BP and CKD Outcomes: Results from the ALLHAT. Clinical journal of the American Society of Nephrology : CJASN, 2016, Mar-07, Volume: 11, Issue:3 Topics: Aged; Amlodipine; Antihyperkalemic Agents; Blood Pressure; Blood Pressure Determination; Chlorthalid	2016
Possible mast cell activation syndrome in a patient undergoing long-term hemodialysis. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2016, Volume: 116, Issue:6 Topics: Aged; Amlodipine; Anaphylaxis; Carbazoles; Carvedilol; Community-Acquired Infections; Deglutition Di	2016
Evaluation of potential drug- drug interactions among Palestinian hemodialysis patients. BMC nephrology, 2016, 07-26, Volume: 17 Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Arabs; Aspirin; Calcium Carbonate; Comorbidity; Diabetes	2016
Association between peritoneal dialysate effluent leukocytosis and amlodipine besylate. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2009, Volume: 53, Issue:3 Topics: Amlodipine; Calcium Channel Blockers; Child, Preschool; Dialysis Solutions; Female; Humans; Kidney F	2009
Amlodipine-induced myoclonus. The American journal of medicine, 2009, Volume: 122, Issue:4 Topics: Aged; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Clonidine; Diuretics; Humans; H	2009
Composite renal endpoints: was ACCOMPLISH accomplished? Lancet (London, England), 2010, Apr-03, Volume: 375, Issue:9721 Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Calcium	2010
[Anti-RNA polymerase III antibodies in scleroderma renal crisis]. Deutsche medizinische Wochenschrift (1946), 2010, Volume: 135, Issue:22 Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors;	2010
Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2012, Volume: 27, Issue:6 Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Creatinine; Di	2012
Antihypertensive drugs and renal protection. JAMA, 2003, Mar-05, Volume: 289, Issue:9 Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive	2003
Summaries for patients. Effects of blood pressure drugs in patients with diabetes and kidney disease. Annals of internal medicine, 2003, Apr-01, Volume: 138, Issue:7 Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Comp	2003
Nitrendipine and amlodipine mimic the acute effects of enalapril on renal haemodynamics and reduce glomerular hyperfiltration in patients with chronic kidney disease. Journal of human hypertension, 2003, Volume: 17, Issue:7 Topics: Adult; Amlodipine; Enalapril; Female; Glomerular Filtration Rate; Hemodynamics; Humans; Kidney Failu	2003
[Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension]. Deutsche medizinische Wochenschrift (1946), 2004, Jan-02, Volume: 129, Issue:1-2 Topics: Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Computer Simulation; Creatinine; Diabetes M	2004
[Type 2 diabetic patient with kidney damage. Sartans banish dialysis risk]. MMW Fortschritte der Medizin, 2004, Jul-08, Volume: 146, Issue:27-28 Topics: Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Diabetes	2004
Summaries for patients. Do the effects of blood pressure drugs differ by kidney function? Annals of internal medicine, 2006, Feb-07, Volume: 144, Issue:3 Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Chronic Disease;	2006
[Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland]. Praxis, 2006, Mar-15, Volume: 95, Issue:11 Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Ca	2006
Chronic kidney disease--a disease domain complex. Geriatrics, 2008, Volume: 63, Issue:3 Topics: Aged; Alendronate; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Asp	2008
Comparative renal hemodynamic effects of lisinopril, verapamil, and amlodipine in patients with chronic renal failure. American journal of hypertension, 1993, Volume: 6, Issue:4 Topics: Amlodipine; Antihypertensive Agents; Dipeptides; Hemodynamics; Humans; Kidney Failure, Chronic; Lisi	1993
Effect of amlodipine therapy on the monoclonal antibody 3G8-induced calcium signal in polymorphonuclear leukocytes of hemodialysis patients. American journal of nephrology, 1999, Volume: 19, Issue:4 Topics: Adult; Amlodipine; Antibodies, Monoclonal; Calcium Channel Blockers; Calcium Signaling; Female; Huma	1999
Severe thrombocytopenia associated with amlodipine treatment. The Annals of pharmacotherapy, 1999, Volume: 33, Issue:10 Topics: Adult; Amlodipine; Antihypertensive Agents; Female; Humans; Hypertension, Renal; Kidney Failure, Chr	1999
Influence of the timing of initiating antihypertensive therapy in hypertensive rats with renal failure. Clinical and experimental hypertension (New York, N.Y. : 1993), 2000, Volume: 22, Issue:5 Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressu	2000
Intensive blood pressure reduction is beneficial in patients with impaired cardiac function coexisting with chronic renal insufficiency. Hypertension research : official journal of the Japanese Society of Hypertension, 2002, Volume: 25, Issue:1 Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Circadian Rhythm; Crea	2002

amlodipine and Chronic Kidney Failure